Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: GRT (Guided Relaxation Training); Other
Lead sponsor: Trinitas Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Elizabeth, New Jersey

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Melanoma (Skin)
Interventions: Aspirin 81 mg, Aspirin 325mg; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer
Interventions: Trametinib, Palbociclib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee • Houston, Texas

Conditions: Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer
Interventions: Polygenic Risk Score; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Obesity
Interventions: behavioral dietary intervention, exercise intervention, soy isoflavones, soy protein isolate, counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment; Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions: Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid; Biological · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Aging
Interventions: Walk With Ease; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years to 59 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, ipilimumab; Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 16 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ear Barotrauma, Middle Ear Disease, Ear Diseases, Pressure Injury, Eustachian Tube Dysfunction, Middle Ear; Injury, Middle Ear Barotrauma
Interventions: Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw), Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw); Procedure
Lead sponsor: Northwell Health; Other
Eligibility: Not listed
Enrollment: 1,553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sleepy Hollow, New York

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus; Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 240 participants
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 44
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 35 more

Conditions: Atopic Dermatitis
Interventions: ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more

Conditions: Breast Cancer
Interventions: Trastuzumab; Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Breast Cancer, Carcinoma, Ductal
Interventions: Intra-Operative Radiotherapy (IORT), Lumpectomy, Whole Breast Radiotherapy, Intracavitary Brachytherapy, Accelerated External Beam 3-D Conformal Radiotherapy, Stereotactic APBI; Radiation · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2029
U.S. locations: 1
States / cities: Stanford, California

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: BG-68501, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis, sargramostim, immunologic technique, synthetic tumor-associated peptide vaccine therapy; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Skin Cancer
Interventions: Increasing hat use; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 8 Years to 11 Years
Enrollment: 2,984 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Melanoma
Interventions: Dendritic Cell Immunization, Cyclophosphamide, Fludarabine, T-Cells, Interleukin-2, Mesna, Intrathecal T-Cells, Intrathecal Interleukin-2; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 1,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 172
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more

Search by objective public record fields.

Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer

Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Molecular and Cellular Characterization of Spongiotic Dermatitis

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study.

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer

Sorafenib in Treating Patients With Metastatic Breast Cancer

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Sun Protection for Florida's Children

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer